Calgary

Calgary, Alberta T2V4R6

0 studies enrolling now · 5 studies all time

What they study most

C. Diff, C. Difficile, CDI, Clostridium Difficile Infection, Clostridium Difficile Infection (CDI), Clostridium Difficile Infection Recurrence, Communicable Diseases, FMT, Fecal Microbiota, Fecal Transplant, Infection, Prostate Cancer

Studies at this site

• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) — Completed
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) — Completed
• Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff — Completed
• Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection — Completed
• A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer — Completed